Compare Teladoc Health Inc (TDOC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teladoc Health Inc vs BIO-TECHNE Corp — how do they compare? Teladoc Health Inc trades at $6.83 (market cap $1.29B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 8.7× Teladoc Health Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| TDOC | TECH | |
|---|---|---|
Market Cap | $1.29B | $11.24B |
Sector | Health | Health |
52-Week High | $9.72 | $72.29 |
52-Week Low | $4.47 | $43.31 |
Enterprise Value | $1.55B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TDOC trades at $7.13, up 6.74% in the last session, but remains under pressure after a 28% drop in August 2026 due to a revenue miss and lowered guidance. The stock shows oversold technical signals with RSI near 24, while fundamentals reveal a net loss margin of -7.13% despite a gross margin of 68.97%. Recent news highlights multiple law firm investigations into securities claims, adding to investor uncertainty.
The outlook is cautious; analyst consensus is a hold with a $8.88 price target, but risks include ongoing losses, competitive pressures, and legal scrutiny. Upside depends on execution in integrated care, but near-term volatility is high.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
